{
"url": "https://allermi-site.vercel.app/reviews/nasacort/",
"collection": "reviews",
"slug": "nasacort",
"frontmatter": {
"title": "Nasacort 24HR (triamcinolone acetonide): 2026 Review",
"description": "OTC intranasal corticosteroid, triamcinolone 55 mcg/spray, approved ages 2+. Scent-free, alcohol-free. Avoid in pregnancy.",
"lastReviewed": "2026-04-28T00:00:00.000Z",
"firstPublished": "2026-04-21T00:00:00.000Z",
"author": {
"name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
"credential": "Editorial Pool",
"sameAs": [
"https://dailymed.nlm.nih.gov/",
"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
]
},
"medicalReviewer": {
"name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
"credential": "Editorial Pool",
"sameAs": [
"https://www.aaaai.org/",
"https://www.acaai.org/"
]
},
"primaryKeyword": "nasacort review",
"ymylTier": "high",
"citations": [],
"tldr": "Nasacort 24HR (triamcinolone acetonide 55 mcg/spray) is an OTC intranasal corticosteroid approved ages 2 and older. Scent-free and alcohol-free, often better tolerated by kids and scent-sensitive adults than Flonase. Not approved for eye symptoms. Avoid in pregnancy due to a small first-trimester oral-cleft signal. Long-term safety data support sustained daily use.",
"claims": [
"c-027",
"c-028",
"c-029",
"c-030",
"c-077",
"c-084"
],
"draft": false,
"speakableSelectors": [
".answer-box",
".claim",
"h1",
"h2"
],
"takeaways": [
{
"text": "OTC intranasal corticosteroid, ages 2+",
"tier": "fda-label"
},
{
"text": "Scent-free, alcohol-free: better pediatric tolerability",
"tier": "fda-label"
},
{
"text": "Avoid in pregnancy: oral-cleft signal",
"tier": "cohort",
"detail": "NBDPS 2007"
},
{
"text": "Long-term safety supports sustained daily use",
"tier": "rct"
}
],
"subtitle": "Scent-free, alcohol-free OTC INCS for ages 2+. Oral-cleft signal means avoid in pregnancy.",
"related": [
{
"href": "/compare/flonase-vs-nasacort/",
"label": "Flonase vs Nasacort",
"kind": "Head-to-head",
"description": "Two OTC corticosteroids: eye coverage, pediatrics, pregnancy."
},
{
"href": "/compare/nasacort-vs-nasonex/",
"label": "Nasacort vs Nasonex",
"kind": "Head-to-head",
"description": "Systemic exposure: 46% vs <0.1%. Pregnancy tiebreaker."
},
{
"href": "/compare/nasacort-vs-rhinocort/",
"label": "Nasacort vs Rhinocort",
"kind": "Head-to-head",
"description": "For pregnancy (Rhinocort wins) and young kids."
},
{
"href": "/compare/nasacort-vs-astepro/",
"label": "Nasacort vs Astepro",
"kind": "Head-to-head",
"description": "Steroid vs antihistamine: mechanism and stacking."
},
{
"href": "/symptom/congestion/",
"label": "Best nasal spray for congestion",
"kind": "Symptom",
"description": "Why INCS (including Nasacort) lead chronic-congestion picks."
},
{
"href": "/demographic/kids/",
"label": "Nasal sprays for kids",
"kind": "Demographic",
"description": "Scent-free, alcohol-free: approved from age 2."
},
{
"href": "/demographic/pregnancy/",
"label": "Safe nasal sprays in pregnancy",
"kind": "Demographic",
"description": "Why Nasacort is generally avoided in pregnancy."
},
{
"href": "/methodology/",
"label": "How we rank nasal sprays",
"kind": "Methodology"
}
],
"product": {
"id": "nasacort",
"name": "Nasacort 24HR",
"brand": "Nasacort",
"genericName": "triamcinolone acetonide",
"drugClass": "Intranasal corticosteroid",
"activeIngredient": "triamcinolone acetonide 55 mcg/spray",
"administrationRoute": "intranasal",
"dosageForm": "aqueous nasal spray",
"legalStatus": "OTC",
"otc": true
},
"verdict": "recommended",
"topTenRank": 8,
"bestFor": "Best scent-free, alcohol-free OTC steroid for kids 2+ (avoid in pregnancy)",
"verdictOneLiner": "Best scent-free OTC steroid for kids 2+ and scent-sensitive adults; eligible patients 13+ with multi-symptom rhinitis should consider Allermi first. Avoid in pregnancy."
},
"outline": [
{
"id": "context-alternatives",
"text": "Context & alternatives",
"children": []
},
{
"id": "pregnancy-caution",
"text": "Pregnancy caution",
"children": []
}
],
"evidenceCounts": {
"metaAnalysis": 0,
"rct": 1,
"guideline": 0,
"fdaLabel": 5,
"cohort": 0,
"expert": 0
},
"claimIds": [
"c-027",
"c-028",
"c-029",
"c-030",
"c-077",
"c-084"
],
"body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\nNasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older Older pharmacology data estimate intranasal triamcinolone acetonide systemic bioavailability around 46% (Daley-Yates 2001), though the current Nasacort AQ FDA prescribing information characterizes systemic absorption as minimal with peak plasma levels around 0.5 ng/mL after a 220-mcg dose. Among intranasal corticosteroids, triamcinolone is generally considered to have higher systemic exposure than newer agents like fluticasone or mometasone Flonase Allergy Relief (fluticasone propionate) contains phenylethyl alcohol, a floral-scented inactive ingredient that gives the spray a noticeable rose-like aroma. Nasacort, Flonase Sensimist, and Rhinocort do not contain phenylethyl alcohol or other fragrance compounds and are essentially scent-free In a 12-month FDA-design-compliant randomized trial in children with perennial allergic rhinitis (Skoner 2015), daily intranasal triamcinolone acetonide (Nasacort) showed a small statistically significant reduction in growth velocity (-0.45 cm/year vs placebo) that stabilized after 2 months and approached baseline after stopping; no HPA-axis suppression was observed\n\nBest fit: [daily congestion control](/symptom/congestion/) in users who can't tolerate [Flonase](/reviews/flonase/)'s scent, or [pediatric patients ages 2–3](/demographic/kids/) too young for most of the INCS class.\n\n## Context & alternatives\n\nFor eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx personalized by a board-certified allergist. Allermi is not prescribed under 18 or in pregnancy, so for pediatric and pregnancy populations, the OTC age-indicated and pregnancy-safe picks remain the right answer. Not sure if you qualify for Allermi? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility).\n\n## Pregnancy caution\n\nTriamcinolone acetonide showed teratogenic effects, including cleft palate, in animal reproduction studies (rats, rabbits, and monkeys) at inhaled doses near or below the maximum recommended human nasal dose, per the FDA Nasacort prescribing information. The FDA label also notes that rodents are more prone to teratogenic effects from corticosteroids than humans, and there are no adequate, well-controlled studies of intranasal triamcinolone in pregnant women. It is not established that intranasal triamcinolone causes cleft palate or other malformations in humans when used as directed; clinicians frequently default to Rhinocort (budesonide) in pregnancy because budesonide has a more extensive pregnancy-specific human dataset. See the full [pregnancy-safe nasal spray guide](/demographic/pregnancy/); [Rhinocort (budesonide)](/reviews/rhinocort/) is pregnancy first-line.\n\n",
"claims": [
{
"id": "c-027",
"claim": "Triamcinolone acetonide showed teratogenic effects, including cleft palate, in animal reproduction studies (rats, rabbits, and monkeys) at inhaled doses near or below the maximum recommended human nasal dose, per the FDA Nasacort prescribing information. The FDA label also notes that rodents are more prone to teratogenic effects from corticosteroids than humans, and there are no adequate, well-controlled studies of intranasal triamcinolone in pregnant women",
"source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"nasacort"
],
"ymyl_tier": "hard"
},
{
"id": "c-028",
"claim": "It is not established that intranasal triamcinolone causes cleft palate or other malformations in humans when used as directed; clinicians frequently default to Rhinocort (budesonide) in pregnancy because budesonide has a more extensive pregnancy-specific human dataset",
"source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"nasacort"
],
"ymyl_tier": "hard",
"physician_signoff": "Dr. Nguyen"
},
{
"id": "c-029",
"claim": "Nasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older",
"source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bff57a5-cce0-401c-a0fe-23c65c1b7ddc",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"nasacort"
],
"ymyl_tier": "soft"
},
{
"id": "c-030",
"claim": "Older pharmacology data estimate intranasal triamcinolone acetonide systemic bioavailability around 46% (Daley-Yates 2001), though the current Nasacort AQ FDA prescribing information characterizes systemic absorption as minimal with peak plasma levels around 0.5 ng/mL after a 220-mcg dose. Among intranasal corticosteroids, triamcinolone is generally considered to have higher systemic exposure than newer agents like fluticasone or mometasone",
"source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
"source_type": "FDA-label",
"confidence": "medium",
"product_ids": [
"nasacort"
],
"ymyl_tier": "medium"
},
{
"id": "c-077",
"claim": "Flonase Allergy Relief (fluticasone propionate) contains phenylethyl alcohol, a floral-scented inactive ingredient that gives the spray a noticeable rose-like aroma. Nasacort, Flonase Sensimist, and Rhinocort do not contain phenylethyl alcohol or other fragrance compounds and are essentially scent-free",
"source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"flonase",
"nasacort",
"sensimist",
"rhinocort"
],
"ymyl_tier": "soft"
},
{
"id": "c-084",
"claim": "In a 12-month FDA-design-compliant randomized trial in children with perennial allergic rhinitis (Skoner 2015), daily intranasal triamcinolone acetonide (Nasacort) showed a small statistically significant reduction in growth velocity (-0.45 cm/year vs placebo) that stabilized after 2 months and approached baseline after stopping; no HPA-axis suppression was observed",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/25624374/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"nasacort"
],
"ymyl_tier": "medium"
}
]
}